ArticleOpen biology2014
Deciphering next-generation pharmacogenomics: an information technology perspective.
Article in Open biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Automated machine learning for genome wide association studies.Bioinformatics (Oxford, England) · 2023Article
- Retrospective pharmacogenetic analysis of a pediatric patient under anticoagulant treatment: Clinical caseBiomedica : revista del Instituto Nacional de Salud · 2021Article
- Challenges of Immune Response Diversity in the Human Population Concerning New Tuberculosis Diagnostics, Therapies, and Vaccines.Frontiers in cellular and infection microbiology · 2020Article
- Actionable Pharmacogenetic Variation in the Slovenian Genomic Database.Frontiers in pharmacology · 2019Article
- Integrating Next-Generation Sequencing in the Clinical Pharmacogenomics Workflow.Frontiers in pharmacology · 2019Review
- Ethical sharing of health data in online platforms - which values should be considered?Life sciences, society and policy · 2017Article
- Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study.The pharmacogenomics journal · 2017Article
- Article
- Minimum information required for a DMET experiment reporting.Pharmacogenomics · 2016Article
- Next-Generation Sequencing: The Translational Medicine Approach from "Bench to Bedside to Population".Medicines (Basel, Switzerland) · 2016Review
- A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.PloS one · 2016Article
- Article
- Advances in the Pharmacogenomics of Adverse Drug Reactions.Drug safety · 2016Review
- Progress in oral personalized medicine: contribution of 'omics'.Journal of oral microbiology · 2015Article
- Whole genome sequencing in pharmacogenomics.Frontiers in pharmacology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the post-genomic era, the rapid evolution of high-throughput genotyping technologies and the increased pace of production of genetic research data are continually prompting the development of appropriate informatics tools, systems and databases as we attempt to cope with the flood of incoming genetic information. Alongside new technologies that serve to enhance data connectivity, emerging information systems should contribute to the creation of a powerful knowledge environment for genotype-to-phenotype information in the context of translational medicine. In the area of pharmacogenomics and personalized medicine, it has become evident that database applications providing important information on the occurrence and consequences of gene variants involved in pharmacokinetics, pharmacodynamics, drug efficacy and drug toxicity will become an integral tool for researchers and medical practitioners alike. At the same time, two fundamental issues are inextricably linked to current developments, namely data sharing and data protection. Here, we discuss high-throughput and next-generation sequencing technology and its impact on pharmacogenomics research. In addition, we present advances and challenges in the field of pharmacogenomics information systems which have in turn triggered the development of an integrated electronic 'pharmacogenomics assistant'. The system is designed to provide personalized drug recommendations based on linked genotype-to-phenotype pharmacogenomics data, as well as to support biomedical researchers in the identification of pharmacogenomics-related gene variants. The provisioned services are tuned in the framework of a single-access pharmacogenomics portal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.